Imugene will forge ahead with a planned pivotal US trial for its blood cancer therapy Azer-cel, having recorded more ‘complete responses’ in its phase 1b study.

6 in 10 Australians haven't written a will - The risks explained 👥 🛑📄
04:53

"Startups are the biggest loser" Founder warns CGT changes could crush innovation 💸 🚨🚀
10:28

Money News with James Willis 💵📊📻 - Monday, 18th May
38:49